Fitzgerald L W, Conklin D S, Krause C M, Marshall A P, Patterson J P, Tran D P, Iyer G, Kostich W A, Largent B L, Hartig P R
CNS Diseases Research, DuPont Pharmaceuticals Research Laboratories, Wilmington, Delaware 19880, USA.
J Neurochem. 1999 May;72(5):2127-34. doi: 10.1046/j.1471-4159.1999.0722127.x.
Many modern models of receptor-G protein function assume that there is a direct relationship between high-affinity agonist binding and efficacy. The validity of this assumption has been recently questioned for the serotonin 5-HT2A receptor. We examined the intrinsic activities of various ligands in activating phosphoinositide hydrolysis and measured their respective binding affinities to the high- and low-affinity states of the 5-HT2C (VNV isoform) and 5-HT(2A) receptors. Ligand binding affinities for the high-affinity state of the receptors were determined using 1-(4-[125I]iodo-2,5-dimethoxyphenyl)2-aminopropane, whereas [3H]mesulergine and N-[3H]methylspiperone were used, in the presence of excess guanine nucleotide [guanosine 5'-O-(3-thiotriphosphate)], to define binding to the low-affinity state of the 5-HT2C and 5-HT2A receptors, respectively. Antagonists labeled the high- and low-affinity states of each receptor with comparable affinities. Previously identified inverse agonists of the 5-HT2C receptor behaved as silent antagonists in our systems even when the receptor was overexpressed at a relatively high density. In contrast, the ability of agonists to bind differentially to the high- and low-affinity states of the 5-HT2A and 5-HT2C receptors was highly correlated (r2 = 0.86 and 0.96, respectively) with their intrinsic activities. These data suggest that high-affinity agonist states can account for agonist efficacy at human 5-HT2A or 5-HT2C receptors without the need for considering additional transition or active states of the receptor-ligand complex. The procedure described herein may expedite drug discovery efforts by predicting intrinsic activities of ligands solely from ligand binding assays.
许多现代的受体 - G蛋白功能模型假定,高亲和力激动剂结合与效能之间存在直接关系。最近,这种假设对于5 - 羟色胺5 - HT2A受体的有效性受到了质疑。我们研究了各种配体激活磷酸肌醇水解的内在活性,并测量了它们与5 - HT2C(VNV亚型)和5 - HT(2A)受体的高亲和力和低亲和力状态的各自结合亲和力。使用1 - (4 - [125I]碘 - 2,5 - 二甲氧基苯基)2 - 氨基丙烷测定受体高亲和力状态的配体结合亲和力,而在过量鸟嘌呤核苷酸[鸟苷5'-O-(3 - 硫代三磷酸)]存在下,分别使用[3H]美舒麦角和N - [3H]甲基螺哌隆来确定与5 - HT2C和5 - HT2A受体低亲和力状态的结合。拮抗剂以相当的亲和力标记每个受体的高亲和力和低亲和力状态。先前鉴定的5 - HT2C受体反向激动剂在我们的系统中表现为沉默拮抗剂,即使受体以相对高密度过表达。相比之下,激动剂与5 - HT2A和5 - HT2C受体高亲和力和低亲和力状态的差异结合能力与其内在活性高度相关(分别为r2 = 0.86和0.96)。这些数据表明,高亲和力激动剂状态可以解释人5 - HT2A或5 - HT2C受体的激动剂效能,而无需考虑受体 - 配体复合物的额外转变或活性状态。本文所述的方法可以通过仅从配体结合试验预测配体的内在活性来加速药物发现工作。